Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab + IVIG for Desensitization in Kidney Transplant
NCT01594424Phase 2Completed
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Jun 2012
- Primary completion
- Nov 2014
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in end stage renal disease (ESRD), sponsored by Cedars-Sinai Medical Center. Started Jun 2012; status: completed.
02
Drugs
tocilizumab
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT01594424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01594424.